thought call continu
resili cf franchis despit
trikafta continu exceed expect even pandem reflect
revenu guidanc rais futur earn expect impact
potenti lower complianc persist could see softer trikafta
number anoth strong quarter vertex guidanc rais midpoint inspir
confid us regard compani fundament driven mainli trikafta
manag highlight patient complianc could come bit suggest slightli
slower growth continu believ trikafta launch remain robust continu
penetr us market along eventu expans ou given continu
evid switch trikafta project higher trikafta revenu
vs consensu expens cf drug overal revenu slightli ahead
guidanc believ conserv still expect
ou reimburs agreement full portfolio reimburs like drive potenti
upsid well repres consensu expect view strong cf base
busi continu outperform allow vertex focu grow pipelin
provid option continu bd given vertex continu execut
commerci perspect insul pandem reiter vertex
top pick along outperform rate tp
despit impact vertex still interest pipelin updat
earlier guidanc state trial would temporarili paus due pandem
still find interest pipelin updat like throughout yearparticularli
scd beta-th vertex expect updat data year addit patient longer
durat therapi saw compel initi data first two patient last year still see
limit credit pipelin given earlier stage develop even current
environ see potenti upsid posit result
model updates/risk ep updat due revis revenu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset
gene-edit system
grey sky scenario model less credit trikafta due lower
expect commerci perform regulatori delay
 close
impact/ pipelin updat overal impact limit far
disrupt suppli chain approv drug cf franchis trikafta
regulatori file eu age older continu review ema
meanwhil compani submit regulatori file trikafta australia
switzerland furthermor vertex plan submit snda trikafta us
patient age year pend final data phase studi
point compani could fulli predict long-term impact cf
franchis especi ou reimburs discuss potenti occur economi
weaken europ beyond look ahead commerci tripl europ think
countri portfolio agreement rel fine commerci perspect
ireland denmark switzerland like germani given open access/ free price
year post-launch may challeng franc still wait deal
symkevi uk given difficulti reimburs orkambi symkevi
earlier stage pipelin vertex temporarili paus screening/ enrol
phase studi antitrypsin defici although studi remain
activ enabl new clinic trial site futur enrol move
compani remain track provid updat data on-going phase studi scd
beta-th includ data addit patient longer durat therapi
due pandem addit patient schedul initi condit right
studi remain activ
focal segment glomerulosclerosi fsg vertex initi phase poc
studi recent semma deal type diabet compani expect initi patient
clinic trial late earli
model adjust increas estim trikafta base strong
revenu evid switch legaci cf drug assum untreat
patient elig symdeko start trikafta furthermor assum high patient
switch trikafta mainli symdeko kalydeco orkambi reduc estim
drug result forecast revenu slightli
revenu guidanc believ conserv guidanc
non-gaap ep weve reduc expens reflect
vertex residu revenu loss incom cs dilut cs charl martineau univers toronto april
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv vertex investig product
commerci sale
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
